Ajanta Pharma · NSE: AJANTPHARM · BSE: 532331
Q3 FY24 results · Oct–Dec 2023
Ajanta Pharma reported revenue from operations of ₹1,105.15 crore (up 13.7% from Q3 FY23) and net profit of ₹210.03 crore (up 56.1% from Q3 FY23) for Q3 FY24 (Oct–Dec 2023), on a consolidated basis.
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,105.15 | 971.77 | +13.7% | 1,028.44 | +7.5% |
| Other income | 13.59 | 34.93 | −61.1% | 21.33 | −36.3% |
| Total income | 1,118.74 | 1,006.70 | +11.1% | 1,049.77 | +6.6% |
| Profit before tax | 290.91 | 168.34 | +72.8% | 275.94 | +5.4% |
| Net profit for the period | 210.03 | 134.51 | +56.1% | 195.30 | +7.5% |
| EPS, basic (₹) | 16.68 | 10.50 | +58.9% | 15.51 | +7.5% |
| Net margin (%) | 19.0 | 13.8 | 19.0 |
| Item | Q3 FY24 | Q3 FY23 | YoY | Q2 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 1,085.29 | 874.89 | +24.0% | 945.18 | +14.8% |
| Other income | 13.73 | 30.51 | −55.0% | 52.16 | −73.7% |
| Total income | 1,099.02 | 905.40 | +21.4% | 997.34 | +10.2% |
| Profit before tax | 305.14 | 154.95 | +96.9% | 290.50 | +5.0% |
| Net profit for the period | 220.15 | 123.96 | +77.6% | 212.36 | +3.7% |
| EPS, basic (₹) | 17.48 | 9.67 | +80.8% | 16.87 | +3.6% |
| Net margin (%) | 20.3 | 14.2 | 22.5 |
Consolidated
- Filed with BSE
- 01 Feb 2024, 15:15 IST
- Board meeting
- 31 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 01 Feb 2024, 15:15 IST
- Board meeting
- 31 Jan 2024
- Period
- 01 Oct 2023 to 31 Dec 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE